Persistent insomnia is among the most frequent complaints in general practice. To identify genetic factors for insomnia complaints, we performed a genome-wide association study (GWAS) and a genome-wide gene-based association study (GWGAS) in 113,006 individuals. We identify three loci and seven genes associated with insomnia complaints, with the associations for one locus and five genes supported by joint analysis with an independent sample (n = 7,565). Our top association (MEIS1, P < 5 × 10 −8 ) has previously been implicated in restless legs syndrome (RLS). Additional analyses favor the hypothesis that MEIS1 exhibits pleiotropy for insomnia and RLS and show that the observed association with insomnia complaints cannot be explained only by the presence of an RLS subgroup within the cases. Sex-specific analyses suggest that there are different genetic architectures between the sexes in addition to shared genetic factors. We show substantial positive genetic correlation of insomnia complaints with internalizing personality traits and metabolic traits and negative correlation with subjective well-being and educational attainment. These findings provide new insight into the genetic architecture of insomnia.
Insomnia disorder is the second most prevalent mental disorder 1 , with prevalence estimates ranging from 10% (adults) to 22% (the elderly) 2, 3 . This disorder is characterized by lasting problems falling asleep or by waking up in the night or early morning, with subjective repercussions for daytime functioning. It is the primary risk factor for depression 4 and contributes to risks of cardiovascular disease [5] [6] [7] [8] [9] , type 2 diabetes 10 and obesity 11 . Heritability estimates of 38% (males) and 59% (females) 12 suggest a substantial role for genetic factors in insomnia disorder. In contrast to the neurobiological mechanisms presumed to be involved in most mental disorders, it has been suggested that insomnia merely involves reversible maladaptive learning of sleep-related cognitions and behaviors 13, 14 . Indeed, interventions that address these activities are at least partly effective in about twothirds of cases 15 , but they ameliorate complaints by only about 50% (ref. 16) , often resulting in a persistent course for the disorder 17 .
Family and twin studies suggest the involvement of genetic factors in the etiology of insomnia [18] [19] [20] [21] . However, only a few linkage and association studies of insomnia-related phenotypes have been conducted, which have mainly been underpowered (n < 5,000), and recent larger studies have used nonvalidated proxy measures for identification of individuals with insomnia disorder [22] [23] [24] . For example, the habitual duration and timing of sleep 25, 26 do not reliably discriminate between cases of insomnia disorder and controls 27 , and genes found to be related to these phenotypes may therefore not be indicative of the biological mechanisms of insomnia. The most recent GWAS for sleep disturbance traits reported several new loci 24 . However, this study did not provide information on the predictive accuracy of the included traits for insomnia disorder, making it difficult to interpret the findings in terms of clinical relevance. In addition, the top finding in this study (MEIS1) is a known risk factor for RLS, and it is still unclear Genome-wide association analysis of insomnia complaints identifies risk genes and genetic overlap with psychiatric and metabolic traits whether the shared associations in this gene reflect causality, partial mediation or pleiotropy 24 .
Here we report a GWAS using the UK Biobank sample 28 (see URLs) including 113,006 individuals (mean age = 56.92 years, s.d. = 7.94 years) to identify genetic risk factors related to insomnia complaints (Online Methods and Supplementary Table 1 ). The discriminative value of insomnia complaints for identifying insomnia disorder cases versus controls was validated in an independent cohort (n = 1,918 individuals). In addition, we report extensively on the possible mechanisms of action for the shared genetic signal in MEIS1 on insomnia complaints and RLS.
RESULTS

Insomnia complaints are predictive of insomnia disorder
Insomnia disorder was assessed using a single question asking individuals whether they have trouble falling asleep at night or wake up in the middle of the night (Supplementary Note and Supplementary  Fig. 1 ). Individuals who answered "usually" were scored as cases, and individuals reporting "never/rarely" or "sometimes" were scored as controls. We note that this operationalization differs from that in ref. 24 , in which the same question in the UK Biobank sample was used but cases were defined as scoring "usually" and controls were defined as scoring "never/rarely" (Supplementary Note). We validated the predictive utility of this question for insomnia disorder in an independent sample of 1,918 participants (845 insomniacs and 1,073 controls) from the Netherlands Sleep Registry 29 (NSR; see URLs; Supplementary Note). The equivalent of the UK Biobank question (using our response category cutoff) in the NSR had a sensitivity of 98% and a specificity of 96% in discriminating questionnaire-defined insomnia disorder cases from unaffected controls (χ 2 = 1356.45, P < 0.0001) and a sensitivity of 0.96 and a specificity of 0.97 in discriminating insomnia disorder cases from cases exclusively having RLS (χ 2 = 639.06, P < 0.0001; Supplementary Note and Supplementary Table 2 ). It did not discriminate well between RLS cases and controls, with a sensitivity of only 0.43 and a specificity of 0.74 (χ 2 = 1.28, P = 0.26; Supplementary Figs. 1 and 2, and Supplementary Table 2) , nor between cases and controls for 19 disease categories possibly related to insomnia (Supplementary Note and Supplementary Fig. 3 ). Further strong support for the validity of the UK Biobank insomnia phenotype was provided by an accuracy of 91% in the classification of clinical insomnia disorder in NSR participants, as diagnosed by a structured interview (Supplementary Note). Moreover, the sleep and mood characteristics of individuals who reported difficulties falling and staying asleep closely resembled the corresponding profile for NSR participants with insomnia disorder but not the profile for those with RLS (Supplementary Note and Supplementary Fig. 4 ). These findings show that the UK Biobank insomnia phenotype is predictive of insomnia disorder with little confounding from comorbidity. We refer to this classification as 'insomnia complaints' hereafter.
Genes implicated by GWAS and functional mechanisms
The prevalence of insomnia complaints was 29% in the UK Biobank sample (Supplementary Table 1 and further descriptives  in Supplementary Table 3) , in keeping with previous estimates for people of advanced age in the UK 30 and elsewhere 31, 32 . Females had a higher prevalence (33%) than males (24%). The sex odds ratio (OR) of 1.37 matches the previously published meta-analysis-derived estimate of 1.41 (ref. 2) . GWAS was performed on all individuals of European descent, and standard quality control procedures included correction for population stratification and filtering based on minor allele frequency (MAF) and imputation quality (Online Methods). The GWAS included 12,444,916 SNPs. The pooled-sex analysis identified two genome-wide significant loci ( Fig. 1a and Table 1 ), implicating two genes in insomnia disorder: MEIS1 on chromosome 2 and SCFD2 on chromosome 4 ( Supplementary Fig. 5a,b) . Sex-specific analyses implicated MEIS1 in females as well, including the same significant SNPs found in the pooled-sex analysis, and an additional locus encompassing WDR27 was identified for males on chromosome 6 (Fig. 1b,c , Table 1 and Supplementary Fig. 5c,d) . Both MEIS1 and WDR27 were identified by the recent GWAS for sleep disturbance traits 24 , which also used UK Biobank data but considered a slightly different insomnia phenotype (Supplementary Note and Supplementary Figs. 6  and 7) . Our most significant SNPs in both genes were the same as in this study, with similar association signals (MEIS1: rs113851554, P = 9.11 × 10 −19 ; WDR27: rs13192566, P = 3.17 × 10 −8 ).
Possible functional mechanisms for the identified SNPs and the SNPs in high linkage disequilibrium (LD) with them (r 2 > 0.6) are reported in the Supplementary Note and Supplementary Table 4 . Most of the genome-wide significant SNPs were intronic and unlikely to be deleterious or were part of a regulatory element. However, the SNPs in the locus on chromosome 6 were associated with increased expression of two neighboring genes in blood cells (PHF10, lowest P = 3.65 × 10 −13 ; C6orf120, lowest P = 3.81 × 10 −13 ). One SNP (rs113851554) in the MEIS1 locus showed evidence (P = 1.08 × 10 −6 , false discovery rate (FDR) < 0.05) of acting as a cis methylation quantitative trait locus (meQTL). Credible set analysis (Online Methods) of the SNPs in the MEIS1 locus identified two variants (rs113851554 and rs182588061) within the 99% confidence set of associated variants that are plausibly the causal variants (Supplementary Table 5 ). When incorporating functional annotation, rs113851554 accounted for the full posterior probability of association, suggesting that the SNP in the MEIS1 locus most strongly associated with insomnia disorder is also the most likely causal SNP.
SNP heritability
SNP-based heritability was estimated to be 0.09 (s.e.m. = 0.0082) by LD score regression 33 (LDSC) and 0.11 (s.e.m. = 0.0093) by BOLT-REML 34 (BR). The sex difference was small, with estimates of 0.12 (s.e.m. = 0.018; LDSC) and 0.11 (s.e.m. = 0.02; BR) in males versus 0.08 (s.e.m. = 0.014; LDSC) and 0.09 (s.e.m. = 0.02; BR) in females. The quantile-quantile plots for all SNPs exhibited only mild inflation (λ all = 1.11; λ males = 1.06; λ females = 1.05; Supplementary  Fig. 8 ), as is expected for a polygenic trait using the current sample size. The intercepts estimated by LD score regression of 1.00, 0.99 and 1.00 for the sex-combined, male-only and female-only analyses, respectively, suggest that this mild inflation is unlikely to be due to population stratification.
Genes implicated by GWGAS
A GWGAS, as implemented in MAGMA 35 (Online Methods), on all individuals identified three genes associated with insomnia complaints: MEIS1 (also implicated by the GWAS), DCBLD1 and MED27. Sex-specific GWGAS identified two additional genes (HHEX and RHCG) for males and two additional genes (IPO7 and TSNARE1) for females ( Fig. 1d-f , Table 2 and Supplementary Table 6 ). Some of these genes have previously been associated with other phenotypes, such as diabetes and schizophrenia (Supplementary Table 7 and Supplementary Note). The most strongly associated gene, MEIS1, encodes a homeobox protein that acts as a transcriptional regulator and activator, and it is thought to be important for normal development 36 . MEIS1 shows the highest expression levels in female internal reproductive organs, but it is also expressed in many other 
Joint analysis with an independent sample
To examine the robustness of the three loci and seven genes that reached genome-wide significance in the primary analyses, we tested their association with a well-defined insomnia phenotype in a sample from deCODE comprising n = 7,565 individuals (Online Methods, Supplementary Note and Supplementary Tables 10-12) and performed meta-analysis of these results together with the UK Biobank association results while adhering to the GWAS significance threshold of P = 5 × 10 −8 (Online Methods and Supplementary  Tables 13 and 14) . The probability of replicating significant SNPs in the deCODE sample was low, owing to the difference in sample size (Supplementary Note and Supplementary Table 15), whereas meta-analysis takes into account the standard errors (sample size) for the observed effects and allows for evaluation of whether discovery P values increase (suggesting no replication) or decrease (supporting a similar effect in the added sample) 38 . The effects of 11 of the 12 SNPs from the full GWAS (both sexes combined) and all 5 SNPs from the female GWAS were sign concordant, whereas those for the 3 SNPs from the male GWAS were not. Only SNPs in the MEIS1 locus (six SNPs in the full GWAS and two SNPs in the female GWAS) showed a stronger association signal for insomnia complaints in the metaanalysis. Six of the seven genes detected in the GWGAS were significant at the genome-wide gene-based threshold of P = 2.72 × 10 −6 in the meta-analysis. The signal for MEIS1, as well as for the four genes found to be associated in the sex-specific analyses, was stronger than in the initial GWGAS and remained below the genome-wide genebased threshold of association in the meta-analysis.
The role of MEIS1 in insomnia complaints and RLS
The gene most strongly associated with insomnia complaints was MEIS1. Winkelmann and colleagues 39, 40 previously reported an association of multiple SNPs in MEIS1 with RLS, and two of our top SNPs were previously associated with clinically diagnosed RLS in a sequencing 41 and gene expression 42 study of MEIS1. RLS is a prevalent disorder characterized by the urge to move the legs, a symptom that has been suggested to involve deficiencies in the dopaminergic system, whereas arousals during sleep, a symptom present in some individuals with RLS, is related to the balance between glutamate and GABA 43 . The latter activity has also been implicated in hyperarousal in insomnia 44 . RLS and insomnia have some form of agitation or restlessness in common, which is expressed primarily in the cognitive domain in insomnia and in the sensorimotor domain in RLS. Given the possible phenotypic overlap between insomnia and RLS and the reported genetic associations in MEIS1 for RLS, we investigated the mechanisms of action that could explain the shared signal in MEIS1 for insomnia complaints and RLS.
First, we investigated whether the observed associations in MEIS1 with insomnia complaints and RLS were independent. At least two signals in MEIS1 are associated with RLS: one including common SNPs reported in refs. 39,40 and a second including low-frequency SNPs reported by refs. 41,42. The RLS-associated SNPs in MEIS1 reported by Winkelmann and colleagues were not genome-wide significant in our insomnia complaints GWAS and were in low LD with our associated SNPs (Supplementary Table 16 ). Conditioning our top SNP, rs113851554, on the RLS-associated SNPs (Online Methods) showed that this SNP has an effect on insomnia complaints (P = 2.90 × 10 −13 ) independent of those of the RLS-associated SNPs in MEIS1. We did not condition on the two SNPs from the second RLS signal in MEIS1 (our top SNP, rs113851554 (ref. 42) , and rs11693221 (ref. 41)), as these SNPs were part of our top association findings for insomnia complaints ( Table 1) .
Second, we applied BUHMBOX 45 , which provided information on the likelihood that a subgroup of individuals with genetic characteristics of RLS existed within the group of individuals with insomnia complaints that could explain our association results (Online Methods). After establishing sufficient power (0.82 reported by the BUHMBOX power calculator, calculated on the basis of sample size, the effect sizes of RLS-associated SNPs and RLS prevalence; Online Methods) to detect heterogeneity when defining RLS genetic structure by the six RLS-associated loci reported in the RLS GWAS 40 (Supplementary Table 17) , we found no evidence that an RLS subgroup by itself was driving the reported associations, both when excluding the MEIS1 locus (P = 0.33) and when including it (P = 0.36). However, after adding our top SNP in MEIS1 for insomnia complaints, which was also previously associated with RLS 42 (P = 4.80 × 10 −12 ), we did find excessive positive correlation between the RLS-associated loci and a subgroup of the individuals reporting insomnia (P = 0.029), although the correlation was driven by this single SNP. Note that, because of a lack of power (due to the small RLS sample size and smaller effect sizes of the insomnia-associated loci), we could not test the reverse hypothesis that an insomnia subgroup drives the RLS associations.
Third, we performed a genetic risk score analysis (Online Methods) to interpret the BUHMBOX results. This yielded a significant association between insomnia complaints and the RLS-associated loci when including the same RLS-associated loci that were tested in BUHMBOX (Supplementary Table 17 ): (i) five RLS loci excluding the MEIS1 locus (P = 7.28 × 10 −3 ); (ii) six RLS loci including the MEIS1 association from the RLS GWAS (P = 6.23 × 10 −4 ); and (iii) six RLS loci including the MEIS1 RLS-associated SNP that was also the top hit for insomnia complaints (P = 5.30 × 10 −13 ). As in the BUHMBOX analysis, including the top signal for insomnia complaints strongly increased the association. The results of the BUHMBOX and genetic risk score analyses together are compatible with pleiotropy, but phenotypic overlap between RLS and insomnia complaints might contribute to the association found in the MEIS1 locus. Summary of the three significant loci present in the full GWAS and/or the male (n = 53,639) and female (n = 59,367) GWAS. All SNPs with P < 5 × 10 −8 in one of the analyses are reported for all three analyses. SNP P values and odds ratios were calculated for each GWAS with an additive genetic model using logistic regression adjusted for age, sex in the full GWAS, genotyping array and principal components. Table 18 ). We note that this sample has strong ascertainment biases due to the COR sample (53% of the combined sample) consisting only of individuals who are relatively old (65 years, on average) and, as members of RLS support groups, tend to have severe RLS. The resulting biases are (i) oversampling of insomnia evoked by severe RLS, as all individuals with insomnia complaints in the COR study necessarily have RLS, and (ii) over-representation of RLS comorbidity with insomnia, as the prevalence of insomnia increases with age and people seeking help for RLS may be more likely to have insomnia as a comorbidity. Taking these biases into consideration, MEIS1 was found to be strongly associated with insomnia complaints, supporting our initial finding, and was associated with RLS as expected ( Supplementary  Tables 19 and 20) . Conditioning the signals for insomnia complaints on those for RLS and vice versa reduced the association signals, indicating that phenotypic overlap contributes to the associations for both phenotypes. However, this reduction in signal, which was complete when conditioning insomnia complaints on RLS but incomplete when conditioning RLS on insomnia complaints, cannot exclude the possibility of pleiotropy at MEIS1 because of the strong ascertainment biases. Up to 83% of all insomnia cases in the combined COR + DHS group may belong to the subgroup in which insomnia complaints are evoked by severe RLS or RLS is a comorbidity (Supplementary  Table 18) , explaining why an effect of MEIS1 on insomnia was not visible after conditioning on RLS.
Fifth, we predicted association P values for insomnia complaints in the UK Biobank sample under the assumption that RLS alone drives the association. To this end, we calculated the expected proportions of individuals with RLS in the UK Biobank insomnia cases and controls, using data on age-specific RLS prevalence 46 , the sensitivity and specificity of the UK Biobank question for RLS, as derived from the NSR and DHS sample, and the reported rs113851554 effect size in RLS cases and controls 42 (Supplementary Note). A χ 2 test yielded a predicted association P value of 2 × 10 −4 (95% confidence interval (CI) = 0.056 to 1.1 × 10 −11 , based on sampling variances; Supplementary Note). This predicted P value under the assumption that the complete signal is driven by an RLS subgroup was much weaker than the actual P value we observed (2.14 × 10 −18 ), and the latter was outside the 95% CI of the predicted P value. This finding thus supports the notion that the effect of MEIS1 on insomnia complaints can, at most, be explained only in part by contamination of the UK Biobank insomnia cases with RLS cases.
Finally, we conducted tests for sign concordance and enrichment of low P values (Online Methods) on the summary statistics for insomnia complaints and RLS (unfortunately, the sample size for the RLS GWAS 40 was insufficient to obtain a reliable estimate of genetic correlation). Seventy-eight percent of the independent top SNPs (P = 1 × 10 −4 ) for insomnia complaints had sign-concordant effects in RLS, whereas 83% of the top SNPs for RLS had sign-discordant effects in insomnia complaints (Supplementary Table 21) . The top signals from the two studies showed little overlap (Supplementary Tables 22  and 23 , and Supplementary Fig. 13 ). This suggests that, besides pleiotropy at some loci, there are genetic factors specific to each of the two disorders.
Taken together, the above results suggest that phenotypic overlap between RLS and insomnia can drive some, but not all, of the association of MEIS1 with insomnia. This confounding effect of RLS on insomnia complaints association likely also occurs in the opposite direction (with insomnia complaints confounding RLS association). Hence, we conclude that MEIS1 is likely to have pleiotropic effects on both RLS and insomnia.
Overlap with sleep-related phenotypes
Data on multiple sleep-related phenotypes are available in the UK Biobank, and multiple loci have been found to be associated with sleep duration 24, 26 , chronotype 25, 26 and excessive daytime sleepiness 24 . We performed GWAS on six additional sleep phenotypes in the UK Biobank ( Supplementary Fig. 14 and Supplementary Table 24 ) and investigated genetic and phenotypic correlations with insomnia complaints (Supplementary Note). Phenotypically, individuals reporting insomnia complaints have shorter sleep duration, more trouble getting up and more periods of unintentional dozing, but they do not show a systematically different chronotype. Furthermore, insomnia complaints showed a significant positive genetic correlation with daytime dozing or sleeping (r g = 0.51, P = 3.25 × 10 −4 ) and napping during the day (r g = 0.42, P = 3.95 × 10 −6 ) and a negative genetic correlation with sleep duration (r g = 0.47, P = 1.97 × 10 −16 ; Supplementary Table 25 ). The loci found to be associated with insomnia complaints showed no significant association with the six additional sleep phenotypes (Supplementary Table 26 ). In addition, we investigated possible confounding by other psychiatric, metabolic and socioeconomic Gene-based P values are reported for all genes significant after Bonferroni correction (α = 2.72 × 10 −6 ) in at least one of the three analyses (full, males, females). P values for loci significantly associated with insomnia are shown in bold. Gene association results in the deCODE sample and the meta-analysis are reported in supplementary tables 12 and 14. GWGAS, genome-wide gene-association study; chr., chromosome; P corrected , P value corrected for multiple testing.
a Reported on GRCh37, including a window of 2.1 kb. b Genome-wide significant in the combined analysis of UK Biobank and deCODE. c Stronger association signal in the combined analysis of UK Biobank and deCODE. Table 27 ).
traits (Online Methods and Supplementary Note). Adjustment of the associations of the significant SNPs for insomnia complaints by these traits did not show evidence that they have confounding effects (Supplementary
Sex-related differences in genetic associations
Females have a higher predisposition for insomnia than males 2 , which might result from sex-related differences in genetic architecture. The genetic correlation between the sexes was estimated to be 0.79 (s.e.m. = 0.13), which is just significantly smaller than 1 (one-sided Wald test, P = 0.045). This estimate is comparable with, for example, that for waist circumference, for which between-sex genetic heterogeneity is expected, in contrast to estimates for height and BMI, where no heterogeneity is found 47 . In keeping with these overall differences, the significant SNP-and gene-based association results also differed between the sexes, except for those in MEIS1 (Fig. 2) . Adding sex as an interaction term to the GWAS on the full sample (Online Methods) did not result in genome-wide significant interactions ( Supplementary  Fig. 15 ), although this finding might also be due to low statistical power for interaction analyses. Tests of sign concordance and enrichment of low P values for sex-specific results showed little evidence for overlap in the top signals between the sexes (Fig. 2 Supplementary Tables 28-30 ), suggesting that sex has a role in evoking specific genetic risk factors of insomnia. Whether X-chromosome loci and sex-specific imprinting 48,49 play a role still needs to be determined. Our finding is in line with sex differences across most sleep variables 50 , including subjective sleep complaints 51 , prevalence 2 and heritability 12 of insomnia, and physiological signatures of sleep, both in the general population 52 and within the population that has insomnia 53 .
, Online Methods and
Functional networks
We applied the heat diffusion algorithm HotNet2 (ref. 54) (Online Methods) to investigate protein-protein interaction networks enriched for the genes most strongly associated with insomnia complaints (P < 0.1) in the full and sex-specific GWGAS (Supplementary Note, Supplementary Table 31 and Supplementary Figs. 16 and 17) . For each input gene, HotNet2 processes a heat diffusion algorithm on the protein-protein interaction network to define a local neighborhood of 'influence' , which is followed by a two-stage multiple-hypothesis test to identify recurrent subnetworks. As input for HotNet2, we selected genes with P < 0.1 from the GWGAS, thereby considering crosstalk across pathways and network topology. In total, we observed 12 subnetworks of genes for males (P = 0.01) and 9 subnetworks for females (P = 0.02; Supplementary Fig. 18 ). These subnetworks significantly overlapped with known pathways that were mostly involved in transcription (Online Methods and Supplementary Table 32 ). In females, one subnetwork involved MEIS1 (Fig. 3a) together with multiple homeobox genes encoding a family of transcription factors important for development. Other subnetworks presented candidate genes at 'hotspots' that were not detected by GWGAS alone; among these, was GNAS in the largest of the subnetworks in females (Fig. 3b) . GNAS is an imprinted gene that is expressed from the maternal chromosome. It has metabolic functions and modulates REM and NREM sleep states 49 . This finding is especially interesting given that stronger maternal transmission 21 , hypermetabolism 55 and instability of these sleep states 56 are all characteristic of insomnia. Future studies will be needed to confirm the involvement of the identified subnetworks in insomnia.
Genetic overlap with other traits
Insomnia implies an increased risk for major health problems, notably in the domains of cardiovascular diseases [5] [6] [7] [8] [9] , obesity 11 and psychiatric disorders like depression 4 . Using whole-genome LD score regression 33 , we assessed the genetic correlation of insomnia with 29 traits from these domains and additional anthropometric and lifestyle traits (Online Methods). Significant genetic correlations (conservatively adjusted for multiple testing: P < 1.72 × 10 −3 (= 0.05/29)) were observed between insomnia complaints and ten other traits (Fig. 4 , left and Supplementary  Table 33 ). Strong positive genetic correlations were observed with anxiety (r g = 0.59, P = 7.14 × 10 −5 ), depressive symptoms (r g = 0.53, P = 1.03 × 10 −17 ), neuroticism (r g = 0.44, P = 1.20 × 10 −25 ) and major depressive disorder (r g = 0.41, P = 6.50 × 10 −4 ). Other positive yet weaker genetic correlations were observed with metabolic traits, including type 2 diabetes, waist circumference, waist-to-hip ratio and body mass index. Strong but negative genetic correlations were observed with subjective well-being (r g = −0.44, P = 5.64 × 10 −11 ) and educational attainment (r g = −0.34, P = 1.81 × 10 −22 ). Of the 29 traits, 18 have also been assessed in the NSR, allowing investigation of the phenotypic differences between these phenotypes in insomnia cases versus controls. We found that the profile of magnitudes for the differences (d) between phenotypic groups a b Figure 3 Protein-protein interaction subnetworks identified by the heat diffusion algorithm HotNet2. The genes most strongly related to insomnia (P < 0.1) in the full and sex-specific GWGAS were used as input to investigate the enrichment of protein-protein interaction networks. Each node (protein) is assigned a score on the basis of the gene P value from the GWGAS. The scores, denoted as 'heat' in HotNet2, diffuse across the edges of the network. We report subnetworks that include genes with a wide range of heat scores: red nodes send and receive a substantial amount of heat, whereas blue nodes do not. Table 34 ), providing further evidence for a link between the abovementioned traits and insomnia.
DISCUSSION
We conducted a large-scale GWAS and GWGAS on insomnia complaints, using a measure that reliably discriminates individuals with insomnia disorders from unaffected controls. We identified five new genes (MEIS1, HHEX, RHCG, IPO7 and TSNARE1) and one locus (encompassing MEIS1) associated with insomnia complaints whose association was supported by joint analysis with an independent sample. These findings partly (two genes) overlapped with those reported in a recently published GWAS 24 using a slightly different operationalization of the phenotype, which was less discriminative of clinical insomnia disorder cases versus controls. The gene most significantly associated with insomnia in our study was MEIS1, which was also found in ref. 24 and has previously been implicated in RLS. Our extensive analyses now show that both residual phenotypic overlap and pleiotropy are relevant in the involvement of MEIS1 in insomnia as well as RLS. We also provide evidence of sex-specific genetic effects and show genetic overlap with several psychiatric and metabolic disorders.
These findings provide starting points for subsequent functional analyses to unravel the molecular neurobiological mechanisms underlying vulnerability to insomnia disorder.
URLs. UK Biobank, http://www.ukbiobank.ac.uk/; Netherlands Sleep Registry, https://www.sleepregistry.nl/; UK Biobank genotyping and quality control, http://biobank.ctsu.ox.ac.uk/crystal/refer. cgi?id=155580; SNPTEST, https://mathgen.stats.ox.ac.uk/genetics_ software/snptest/snptest.html; MAGMA, http://ctg.cncr.nl/software/ magma; Sanger Imputation Service, https://imputation.sanger.ac.uk/; genotyping chip strand files, http://www.well.ox.ac.uk/~wrayner/ strand/; dbSNP data, ftp://ftp.ncbi.nih.gov/snp/; PLINK, https:// www.cog-genomics.org/plink2; BUHMBOX, http://software. broadinstitute.org/mpg/buhmbox/; METAL, http://genome. sph.umich.edu/wiki/METAL_Program; MSigDB, http://software. broadinstitute.org/gsea/msigdb/; LD score regression, https://github. com/bulik/ldsc.
METhODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper. table 33 ). Error bars represent standard errors on these estimates. Red bars represent traits that showed a significant genetic correlation after correction for multiple testing (P < 1.72 × 10 −3 ), pink bars represent traits that showed nominal association (P < 0.05) and blue bars represent traits that did not show a significant genetic association. Right, the genetic correlations profile was strikingly similar to phenotypic overlap of insomnia with the same subject characteristics assessed in an independent sample. Of the 29 disorders, traits and characteristics, 18 had been assessed in the NSR as well. Group differences between the 1,073 individuals without insomnia complaints and the 845 individuals likely to have insomnia disorders were evaluated using t tests (continuous phenotypes) or χ 2 tests (dichotomous phenotypes) ( supplementary  table 34 ). The profile of the magnitudes (d) of phenotypic group differences strongly resembled the genetic correlation profiles. NS, not significant. 
ONLINE METhODS
UK Biobank sample.
We used data provided by the UK Biobank Study 28 (see URLs). UK Biobank is a major national health resource including >500,000 participants, with the aim of improving the prevention, diagnosis and treatment of a wide range of serious and life-threatening illnessesincluding cancer, heart diseases, stroke, diabetes, arthritis, osteoporosis, eye disorders, depression and forms of dementia. All participants provided written informed consent; the UK Biobank received ethical approval from the National Research Ethics Service Committee North West-Haydock (reference 11/NW/0382), and all study procedures were performed in accordance with the World Medical Association Declaration of Helsinki ethical principles for medical research. The current study was conducted under UK Biobank application number 16406. The study design of the UK Biobank has been described elsewhere 28, 57 . Briefly, in 2006-2010, about 9.2 million invitation letters to participate in the study were sent to all people aged 40-69 years who were registered with the National Health Service and living up to ~25 miles from one of the 22 study assessment centers. A total of 503,325 participants were recruited into the study 28 . Apart from registry-based phenotypic information, extensive self-reported baseline data were collected by questionnaire, in addition to anthropometric assessments and DNA collection. For the present study, we focused on insomnia, which was measured as experiencing trouble falling asleep or waking up in the middle of the night (Supplementary Note,) . SNP analysis of the UK Biobank sample. We used imputed genetic data from UK Biobank (May 2015 release) including ~73 million genetic variants in 152,249 individuals. Details on the data are provided elsewhere (see URLs). In summary, the first ~50,000 samples were genotyped on the UK BiLEVE custom array, and the remaining ~100,000 samples were genotyped on the UK Biobank Axiom array. After standard quality control of the SNPs and samples, which was centrally performed by UK Biobank, the data set comprised 641,018 autosomal SNPs in 152,256 samples for phasing and imputation. Imputation was performed with a reference panel that included the UK10K haplotype panel and the 1000 Genomes Project Phase 3 reference panel.
For analyses in our study, we selected only individuals of European descent. After removal of related individuals and individuals with discordant sex, who withdrew consent and who had missing phenotype data, 113,006 individuals remained for analysis (Supplementary Table 1) . This is the largest available GWAS sample for insomnia to date. Previous power analyses showed that a sample size of n = 40,000 individuals allows for high-power (>90%) detection of SNPs with small effect sizes explaining only 0.1% of the variance 58 , indicating sufficient statistical power to detect SNPs associated with insomnia in our sample.
Association tests were performed in SNPTEST 59 (see URLs) using logistic regression with the covariates age, sex (for the full sample), genotyping array, the top five genetically determined principal components and additional principal components out of ten further ones that were associated with the phenotype (tested by logistic regression). SNPs with imputation quality of <0.8 (based on the total sample and only those of European ancestry) and a MAF of <0.001 were excluded after the association analysis, resulting in 12,444,916 SNPs, 12,428,592 SNPs and 12,432,937 SNPs for the full, male and female analyses, respectively. Gene analysis. We used all 19,427 protein-coding genes from the NCBI 37.3 gene definitions as the basis for a GWGAS in MAGMA 35 (see URLs). We annotated all SNPs in our association analysis to these genes, resulting in 18,355 genes that were covered by at least one SNP. We included a window around each gene of 2 kb before the transcription start site and 1 kb after the transcription stop site. Gene association tests were performed taking into account the LD between SNPs. We applied a stringent Bonferroni correction to account for multiple testing.
A GWGAS can identify genes in which multiple genetic variants show mild effects that are not sufficiently strong to be detected by GWAS. On the other hand, although a GWAS analysis can indicate a significant locus encompassing a gene, it is possible for this gene not to be identified by GWGAS because a gene can harbor many more SNPs that do not show an association signal and the GWGAS takes all SNPs within the gene into account.
SNP analysis of the deCODE sample. The Icelandic GWAS data set used in the current study is based on whole-genome sequencing, chip genotyping and long-range phasing of Icelandic population samples 60 . In brief, we performed whole-genome sequencing of 15,220 Icelanders using Illumina technology to an average depth of at least 34×, resulting in the identification of ~94 million variants. Using imputation assisted by long-range haplotype phasing 61 and after removing variants with imputation information content of <0.8 as well as an imputed MAF of <0.01%, we successfully inferred the genotypes of 32,463,443 variants in 434,571 Icelanders, of whom 151,677 had been genotyped using the Illumina chip genotyping platform. The remaining 282,894 Icelanders are first-and second-degree relatives of the chip-typed individuals and were imputed through the aid of genealogical information. Of the 3,774 cases and 3,791 controls used in this study, 3,671 and 3,697 were directly genotyped, respectively.
Logistic regression was used to test for associations between variants and insomnia, assuming a multiplicative model treating disease status as the response and using expected genotype counts from imputation as covariates. For the Icelandic cohort, this was done using software developed at deCODE Genetics 60 . Testing was performed using the likelihood-ratio statistic, and population stratification was adjusted for by including county of birth as a covariate.
To account for inflation in test statistics due to cryptic relatedness and stratification within the case and control sample sets, we applied the method of LD score regression 33 . With a set of 1.1 million variants, we regressed the χ 2 statistics from our GWAS scan against LD score and used the intercept as a correction factor. The estimated correction factors were 1.059, 1.025 and 1.036 for the analyses including all individuals, males only and females only, respectively. All P values were adjusted using these correction factors.
Genotyping and association analyses of the COR and DHS samples.
Genotyping was performed on 1,051 DHS participants using the Illumina HumanOmni Chip 2.5-4v1 and the GenomeStudio Genotype module. A total of 1,057 COR study participants were genotyped using the Affymetrix Axiom CEU array and the Axiom GT1 algorithm. Genome-wide imputation of autosomal SNPs according to Phase 3 of the 1000 Genomes Project was performed at the Sanger Imputation Service (see URLs). Quality control before imputation removed variants with a genotyping rate of <95%, a MAF of <10 × 10 −3 or strong deviation from Hardy-Weinberg equilibrium (P < 10 × 10 −8 ), and it excluded individuals with sex mismatch or a genotyping rate of <95%, finally selecting a maximum set of unrelated individuals (π > 0.16). Variants were recoded before imputation according to human genome build 37 information on position, strand orientation and major alleles, as reported by genotyping chip strand files (see URLs) and dbSNP (see URLs). Recoded data sets were merged using PLINK software 62 (see URLs) and subjected to multidimensional scaling (MDS) on ten dimensions, which involved outlier detection (>4 s.d. above or below the population mean) and provided covariates besides age and sex for the association analyses. For the latter, the imputed genotypes were merged, yielding data on 1,985 individuals after quality control and outlier removal. For 1,772 of these individuals, the three-level insomnia severity score was available. In the case of individual SNPs, association analysis was applied as an additive model and linear or logistic regression, as implemented in PLINK. For the gene analysis, MAGMA was applied with the same phenotypes and covariates, using the same method in MAGMA as for the GWGAS.
Credible set analysis. For the MEIS1 locus, we defined a credible set of SNPs that could plausibly be considered as causal using PAINTOR (probabilistic annotation integrator) 63 . PAINTOR uses a multivariate normal approximation to connect the LD structure of the SNPs in a locus to P values. Data on functional annotation are integrated through an empirical Bayes prior, resulting in a prior probability of a variant being causal that is governed by its score in the functional classes. The SNPs scoring high for certain functional annotations are upweighted, while the SNPs scoring low for a certain functional annotation are downweighted. We included the functional annotations reported in the Supplementary Note to prioritize the SNPs in the MEIS1 locus, including deleteriousness (continuous score), regulatory function (continuous score), meQTL (yes/no) and mean chromatin state over different tissues (continuous score).
